Pure Global AI
NCT06076486Recruiting

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated Pain
Nanjing Chia-tai Tianqing PharmaceuticalPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Endometriosis
Drug/Device/Intervention
Elagolix
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Nanjing Chia-tai Tianqing Pharmaceutical
Location
Beijing, China
Timeline & enrollment
Phase
Phase 3
Start date
Sep 14, 2023
End date
Sep 30, 2026
Enrollment
330 participants
Primary outcome

Percentage of responders of dysmenorrhea (DYS) at week 12,Percentage of responders of Non-Menstrual Pelvic Pain (NMPP) at week 12

Summary

This is a phase 3, multicenter, double-blind, placebo-controlled, randomized study to
 evaluate the efficacy and safety of elagolix tablets versus placebo in premenopausal women
 with moderate or severe endometriosis-associated pain.

ICD-10 classifications
EndometriosisOther endometriosisEndometriosis, unspecifiedEndometriosis of uterusEndometriosis of ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06076486
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06076486 through Pure Global AI's free database. This Phase 3 trial is sponsored by Nanjing Chia-tai Tianqing Pharmaceutical and is currently Recruiting. The study focuses on Endometriosis. Target enrollment is 330 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.